🔎 Trials Near Me

Beranda › Epilepsi › Illinois

Uji klinis Epilepsi di Illinois

7 studi untuk Epilepsi mencari peserta di lokasi di Illinois.

Kota di Illinois

Teks studi resmi (Bahasa Inggris)

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

  • Re:Cognition Health-Chicago, Chicago
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07594119

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  • Southern Illinois University School of Medicine, Springfield
Menerima pesertaFase 3
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT05667142

Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Menerima pesertaStudi observasional
Hingga usia 26 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT05374824

A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

  • Praxis Research Site, Chicago
Menerima pesertaFase 3
1 Day – 18 Years · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT07019922

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

  • Rush University Medical Center, Chicago
  • University of Chicago, Chicago
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 9 Jun 2026 · NCT05135091

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

  • Southern Illinois University School of Medicine, Springfield
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT05716100

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

  • Lurie Children's Hospital of Chicago, Chicago
Menerima pesertaFase 2
1 Day – 6 Months · Semua jenis kelamin · Diperbarui 22 Jan 2026 · NCT05104983

Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.